Cardiovascular disease is the leading cause of death for incarcerated individuals. Unfortunately, heart failure is a challenge for clinicians to accurately manage, even as more research and drug therapy becomes available. We will review the recently updated 2021 ACC/AHA clinical practice guidelines, review landmark clinical trials, and highlight new and emerging therapies in heart failure. Learn how to integrate a new evidence-based standard of care and best practices into your treatment of heart failure.
Distinguish between established heart failure therapies for reduced (HFrEF) and preserved (HFpEF) ejection fraction
Recognize the expanded role for ARNIs in HFrEF and HFpEF, as well as the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of HFrEF
Review new and emerging evidence-based therapies in conjunction with recently updated ACC/AHA guidelines
Henry So PharmD, BS, Diamond Pharmacy Services & Medical Supply